Effect of bisphosphonates on pain and quality of life in patients with bone metastases (Q34015944)

30 July 2017

1 reference

title

Effect of bisphosphonates on pain and quality of life in patients with bone metastases (English)

1 reference

30 July 2017

0 references

1 reference

Luis Costa

1

0 references

author name string

Pierre P Major

series ordinal

2

1 reference

30 July 2017

publication date

3 February 2009

1 reference

Nature Clinical Practice Oncology

30 July 2017

published in

1 reference

30 July 2017

volume

6

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

163-174

1 reference

Clodronate for treatment of bone metastases in hormone refractory prostate cancer

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1323

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1323

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1323

The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1323

Skeletal complications of malignancy

21 January 2018

1 reference

12 December 2020

Sequential changes in vessel formation and micro-vascular function during bone repair

1 reference

12 December 2020

Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology

1 reference

12 December 2020

The role of bisphosphonates in the management of prostate cancer

1 reference

12 December 2020

The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer

1 reference

12 December 2020

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

1 reference

12 December 2020

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

1 reference

12 December 2020

Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden

1 reference

12 December 2020

Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study

1 reference

12 December 2020

Bisphosphonates for breast cancer

1 reference

12 December 2020

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

1 reference

12 December 2020

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

1 reference

12 December 2020

Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.

1 reference

12 December 2020

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

12 December 2020

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

1 reference

12 December 2020

Pathologic fractures due to metastatic disease. A retrospective study of 160 surgically treated fractures.

1 reference

12 December 2020

The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer

1 reference

12 December 2020

Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment

1 reference

12 December 2020

Radionuclide therapy for palliation of pain due to osteoblastic metastases

1 reference

12 December 2020

Management of bone metastases in breast cancer

1 reference

12 December 2020

Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer

1 reference

12 December 2020

Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study

1 reference

12 December 2020

Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents

1 reference

12 December 2020

Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer

1 reference

12 December 2020

Bone integrity and bone metastases in breast cancer

1 reference

12 December 2020

Pathophysiology of bone cancer pain.

1 reference

12 December 2020

Pain assessment: global use of the Brief Pain Inventory

1 reference

12 December 2020

Pain flare following external beam radiotherapy and meaningful change in pain scores in the treatment of bone metastases

1 reference

12 December 2020

The role of disodium pamidronate in the management of bone pain due to malignancy

1 reference

12 December 2020

Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.

1 reference

12 December 2020

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

1 reference

12 December 2020

Pathogenesis and pharmacological treatment of bone pain in skeletal metastases

1 reference

12 December 2020

Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases

1 reference

12 December 2020

The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population

1 reference

12 December 2020

Discovery, clinical development, and therapeutic uses of bisphosphonates

1 reference

12 December 2020

A mechanism-based understanding of bone cancer pain.

1 reference

12 December 2020

Burden of bone disease

1 reference

12 December 2020

Advances in the treatment of bone metastases

1 reference

12 December 2020

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

1 reference

12 December 2020

The rapid access palliative radiotherapy program: blueprint for initiation of a one-stop multidisciplinary bone metastases clinic

1 reference

12 December 2020

Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy

1 reference

12 December 2020

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

12 December 2020

Measuring the quality of life of cancer patients: a concise QL-index for use by physicians.

1 reference

12 December 2020

Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients

1 reference

12 December 2020

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials

1 reference

12 December 2020

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

12 December 2020

Exploring the anti-tumour activity of bisphosphonates in early breast cancer.

1 reference

12 December 2020

Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study

1 reference

12 December 2020

Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications

1 reference

12 December 2020

Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells

1 reference

12 December 2020

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

12 December 2020

Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.

1 reference

12 December 2020

The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer

1 reference

12 December 2020

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

1 reference

12 December 2020

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

1 reference

12 December 2020

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

1 reference

12 December 2020

Bone-directed treatments for prostate cancer

1 reference

12 December 2020

The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer

1 reference

12 December 2020

Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Bisphosphonates: preclinical review

1 reference

12 December 2020

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

1 reference

12 December 2020

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

1 reference

12 December 2020

Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial

1 reference

12 December 2020

Transient relief of metastatic cancer bone pain by oral administration of etidronate

1 reference

12 December 2020

The lethal phenotype of cancer: the molecular basis of death due to malignancy

1 reference

12 December 2020

The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer

1 reference

12 December 2020

Palliative radiotherapy for metastatic bone tumor

1 reference

12 December 2020

Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer

1 reference

12 December 2020

Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review

1 reference

12 December 2020

Bone-seeking radionuclides for therapy

1 reference

12 December 2020

Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study

1 reference

12 December 2020

Emerging anti-cancer molecular mechanisms of aminobisphosphonates

1 reference

12 December 2020

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

1 reference

12 December 2020

Bisphosphonates: clinical experience

1 reference

12 December 2020

Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy

1 reference

12 December 2020

Opioid analgesia: perspectives on right use and utility.

1 reference

12 December 2020

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain

1 reference

12 December 2020

Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients

1 reference

12 December 2020

Integrative oncology: complementary therapies for pain, anxiety, and mood disturbance

1 reference

12 December 2020

Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid

1 reference

12 December 2020

The last 3 days of life in three different care settings in The Netherlands

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1323

7 January 2021

inferred from DOI database lookup

Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1323

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NCPONC1323

1 reference

release_vrfoga7mznbvxcyxfrmlushsyu

30 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vrfoga7mznbvxcyxfrmlushsyu

24 November 2022

mapped directly with Wikidata item

1 reference